Sign up to save your podcasts
Or
Share Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.
View all episodes
By RBC Capital Markets
5
1212 ratings
In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,221 Listeners
WSJ Your Money Briefing
1,720 Listeners
Exchanges
973 Listeners
Odd Lots
1,898 Listeners
WSJ Tech News Briefing
1,640 Listeners
a16z Podcast
1,101 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
324 Listeners
Wall Street Breakfast
1,041 Listeners
Thoughts on the Market
1,307 Listeners
The Journal.
6,076 Listeners
BioCentury This Week
34 Listeners
RBC's Markets in Motion
40 Listeners
Biotech Hangout
19 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
74 Listeners
Strategic Alternatives
18 Listeners
The Top Line
15 Listeners
Macro Minutes
3 Listeners